Welcome to our dedicated page for Immuneering news (Ticker: IMRX), a resource for investors and traders seeking the latest updates and insights on Immuneering stock.
Immuneering Corporation reports clinical oncology developments centered on Deep Cyclic Inhibitors, a category of cancer medicines the company is developing for durability, tolerability and combinability. Its lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK being studied across MAPK pathway-driven tumors, including pancreatic cancer.
Recurring updates include survival and safety data from atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, molecular and circulating tumor DNA analyses tied to MAPK resistance mechanisms, and presentations at oncology meetings such as ASCO and AACR. Company news also covers financial results, R&D spending, pipeline strategy, regulatory-readiness activities and healthcare-conference presentations.
Immuneering Corporation (Nasdaq: IMRX) announced it will present data on its second program, IMM-6-415, at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 8-12, 2022, in Boston. The poster presentation, titled Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the dual MEK inhibitor, IMM-6-415, highlights its potential in enhancing PD1 and CTLA4 checkpoint blockade for RAS mutant tumors. IMM-6-415 is a third-generation dual MEK inhibitor aimed at improving cancer therapies for patients with solid tumors driven by RAS mutations.
Immuneering Corporation (Nasdaq: IMRX) has received FDA clearance for its Investigational New Drug (IND) application for IMM-1-104, enabling the initiation of a Phase 1/2a clinical trial targeting advanced RAS mutant solid tumors. The trial, anticipated to start in Q4 2022, aims to evaluate the safety, tolerability, and preliminary anti-cancer activity of this novel drug. This trial is notable for including patients with any RAS mutation, marking a significant step towards expanding treatment options for cancer patients with solid tumors driven by RAS mutations.
Pyramid Biosciences has expanded its leadership team by appointing Biren Amin as Chief Financial and Strategy Officer. Amin, previously CFO at Immuneering Corporation (NASDAQ: IMRX), brings over two decades of experience in oncology and biotechnology. The company is focused on developing precision therapies for cancer, particularly with its lead program PBI-200, a TRK inhibitor for NTRK fusion-driven cancers. The CEO expressed confidence in Amin's expertise to guide corporate strategy and advance the product pipeline during a period of significant growth for the company.
Immuneering Corporation (Nasdaq: IMRX) has submitted an Investigational New Drug (IND) application to the FDA for its oral small molecule, IMM-1-104, aimed at treating advanced RAS mutant solid tumors. This third generation MEK inhibitor is designed for broad pan-RAS activity and has shown robust anti-tumor effects in preclinical models, including KRAS mutant cancers. The company plans to initiate a Phase 1/2a clinical trial, with expectations to enroll the first patient in Q4 2022, pending regulatory approval.
Immuneering Corporation (Nasdaq: IMRX) will participate in two investor conferences in September 2022, focusing on its drug pipeline and business strategy. CEO Ben Zeskind and CSO Brett Hall will represent the company. Key dates include the Wells Fargo Healthcare Conference on September 8 in Boston and the Morgan Stanley Global Healthcare Conference on September 14 in New York, featuring a fireside chat at 2:05 pm ET. Immuneering aims to enhance cancer treatment through its innovative pipeline, including the lead candidate IMM-1-104, targeting advanced solid tumors.
Immuneering Corporation (NASDAQ: IMRX) announced its financial results for Q2 2022, reporting a net loss of $11.5 million, or $0.44 per share, up from $8.0 million, or $1.61 per share, in Q2 2021. The company holds $128.1 million in cash and equivalents, sufficient to fund operations until Q3 2024. Upcoming milestones include filing an IND for IMM-1-104, targeting RAS mutation-driven tumors, this quarter, and the first patient enrollment in Q4 2022. Additionally, an IND for IMM-6-415 is expected in 2023.
Immuneering Corporation (Nasdaq: IMRX) announced its participation at the William Blair Biotech Focus Conference 2022 on July 13, 2022. CEO Ben Zeskind will be part of a panel discussing pre-clinical data related to the company’s lead product candidate, IMM-1-104, which targets pan-KRAS/NRAS activity in advanced solid tumors. Immuneering’s innovative approach combines translational bioinformatics with unique drug design strategies to enhance treatment outcomes for cancer patients, leveraging its proprietary 3D tumor modeling and bioinformatics platforms.
Immuneering Corporation (NASDAQ: IMRX) announced preclinical data for its dual-MEK inhibitor, IMM-1-104, showing significant tumor growth inhibition (TGI) in pancreatic cancer models with KRAS mutations. The drug demonstrated TGI of 49-84% against KRAS-G12V mutant tumors, outperforming existing treatments like sotorasib and adagrasib. The company plans to submit an IND in Q3 2022 and start Phase 1 trials in Q4 2022. These findings suggest IMM-1-104 has potential broad activity against various tumors driven by MAPK mutations, positioning it favorably in oncology.
Immuneering Corporation (NASDAQ: IMRX) will present its business strategy and pipeline at the Jefferies Healthcare Conference on June 8, 2022, and the H.C. Wainwright Global Investment Conference from May 24-26, 2022. Ben Zeskind, CEO, and Brett Hall, CSO, will lead the Jefferies presentation, which is a moderated fireside chat. The presentation will be available for live streaming and archived for 30 days. Immuneering focuses on developing oncology and neuroscience products using a unique translational bioinformatics platform, with key candidates including IMM-1-104 and IMM-6-415.
Immuneering Corporation (NASDAQ: IMRX) announced its first quarter 2022 financial results, reporting a net loss of $12.9 million ($0.49 per share). The company has $137.8 million in cash, expected to provide a runway into Q3 2024. Key developments include the anticipated IND filing for IMM-1-104 in Q3 2022 and patient enrollment in Q4 2022, with encouraging preclinical results across various tumor models. R&D expenses rose to $9.1 million, reflecting increased preclinical costs. Additionally, the second IND for IMM-6-415 is expected in 2023.